한글목차

XP-3924는 두 가지 보완적 치료제인 프람린타이드(amylin analogues)와 인슐린의 시너지 효과를 개선합니다. 이 두 가지 기존 치료제를 별도로 병용 투여하면 식후 혈당 상승과 혈당 변동을 모두 억제하여 전반적인 혈당 조절을 개선할 수 있습니다.

앞으로 수년간 제1형 당뇨병 시장 시나리오는 세계에서 광범위한 조사와 의료비 지출 증가로 인해 변화할 것입니다. 각 업체들은 질환을 치료/개선하기 위한 새로운 접근 방식에 초점을 맞춘 치료법을 개발하고, 과제를 평가하고, XP-3924의 우위에 영향을 미칠 수 있는 기회를 모색하고 있으며, 제1형 당뇨병에 대한 다른 신흥 제품들이 XP-3924와 치열한 시장 경쟁을 벌일 것으로 예상됩니다. 후발주자 신약이 출시되면 시장에 큰 영향을 미칠 것으로 예상됩니다.

주요 7개국의 XP-3924 시장에 대해 조사했으며, 시장의 개요와 2027-2032년 판매 예측 데이터, 경쟁 구도 및 국가별 동향 등을 제공하고 있습니다.

목차

제1장 리포트의 서론

제2장 1형 당뇨병에 대한 XP-3924의 개요

• 제품 상세
• 임상 개발
  • 임상 연구
  • 임상시험 정보
  • 안전성과 유효성
• 기타 개발 활동
• 제품 개요

제3장 경쟁 구도(출시 치료법)

제4장 경쟁 구도(후기 단계 신규 치료법)

제5장 XP-3924 시장 평가

• 1형 당뇨병에 대한 XP-3924 시장 전망
• 주요 7개국 시장 분석
  • 주요 7개국에서 1형 당뇨병에 대한 XP-3924의 시장 규모
• 국가별 시장 분석
  • 미국
  • 독일
  • 영국

제6장 SWOT 분석

제7장 애널리스트의 견해

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 DelveInsight 소개

제12장 리포트 구입 옵션

영문목차

“"XP-3924 Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about XP-3924 for type 1 diabetes mellitus in the seven major markets. A detailed picture of the XP-3924 for type 1 diabetes mellitus in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the XP-3924 for type 1 diabetes mellitus. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the XP-3924 market forecast analysis for type 1 diabetes mellitus in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in type 1 diabetes mellitus.

Drug Summary:

XP-3924 improves the synergistic combination of two complementary therapies - pramlintide (an amylin-analog) and insulin. The separate administration of these existing therapies in combination reduces both postprandial glucose excursions and glucose variability and improves overall glycemic control.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the XP-3924 description, mechanism of action, dosage and administration, research and development activities in type 1 diabetes mellitus.
• Elaborated details on XP-3924 regulatory milestones and other development activities have been provided in this report.
• The report also highlights the XP-3924 research and development activities in type 1 diabetes mellitus across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around XP-3924.
• The report contains forecasted sales of XP-3924 for type 1 diabetes mellitus till 2032.
• Comprehensive coverage of the late-stage emerging therapies for type 1 diabetes mellitus.
• The report also features the SWOT analysis with analyst views for XP-3924 in type 1 diabetes mellitus.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

XP-3924 Analytical Perspective by DelveInsight

In-depth XP-3924 Market Assessment

This report provides a detailed market assessment of XP-3924 for type 1 diabetes mellitus in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

XP-3924 Clinical Assessment

The report provides the clinical trials information of XP-3924 for type 1 diabetes mellitus covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for type 1 diabetes mellitus is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence XP-3924 dominance.
• Other emerging products for type 1 diabetes mellitus are expected to give tough market competition to XP-3924 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of XP-3924 in type 1 diabetes mellitus.
• Our in-depth analysis of the forecasted sales data of XP-3924 from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the XP-3924 in type 1 diabetes mellitus.

Key Questions:

• What is the product type, route of administration and mechanism of action of XP-3924?
• What is the clinical trial status of the study related to XP-3924 in type 1 diabetes mellitus and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the XP-3924 development?
• What are the key designations that have been granted to XP-3924 for type 1 diabetes mellitus?
• What is the forecasted market scenario of XP-3924 for type 1 diabetes mellitus?
• What are the forecasted sales of XP-3924 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to XP-3924 for type 1 diabetes mellitus?
• Which are the late-stage emerging therapies under development for the treatment of type 1 diabetes mellitus?

Table of Contents

1. Report Introduction

2. XP-3924 Overview in type 1 diabetes mellitus

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. XP-3924 Market Assessment

• 5.1. Market Outlook of XP-3924 in type 1 diabetes mellitus
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of XP-3924 in the 7MM for type 1 diabetes mellitus
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of XP-3924 in the United States for type 1 diabetes mellitus
  • 5.3.2. Market Size of XP-3924 in Germany for type 1 diabetes mellitus
  • 5.3.3. Market Size of XP-3924 in France for type 1 diabetes mellitus
  • 5.3.4. Market Size of XP-3924 in Italy for type 1 diabetes mellitus
  • 5.3.5. Market Size of XP-3924 in Spain for type 1 diabetes mellitus
  • 5.3.6. Market Size of XP-3924 in the United Kingdom for type 1 diabetes mellitus
  • 5.3.7. Market Size of XP-3924 in Japan for type 1 diabetes mellitus

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options